[go: up one dir, main page]

BR0212036A - Composições farmacêuticas compreendendo conjugados de polissacarìdeos para a inibição da metástase ou prevenção da recorrência de tumor maligno - Google Patents

Composições farmacêuticas compreendendo conjugados de polissacarìdeos para a inibição da metástase ou prevenção da recorrência de tumor maligno

Info

Publication number
BR0212036A
BR0212036A BR0212036-4A BR0212036A BR0212036A BR 0212036 A BR0212036 A BR 0212036A BR 0212036 A BR0212036 A BR 0212036A BR 0212036 A BR0212036 A BR 0212036A
Authority
BR
Brazil
Prior art keywords
malignant tumor
pharmaceutical compositions
inhibiting metastasis
preventing recurrence
polysaccharide
Prior art date
Application number
BR0212036-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Takayuki Kawaguchi
Satoshi Okuno
Toshiro Yano
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of BR0212036A publication Critical patent/BR0212036A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR0212036-4A 2001-08-21 2002-08-16 Composições farmacêuticas compreendendo conjugados de polissacarìdeos para a inibição da metástase ou prevenção da recorrência de tumor maligno BR0212036A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001249717 2001-08-21
PCT/JP2002/008309 WO2003015826A1 (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor

Publications (1)

Publication Number Publication Date
BR0212036A true BR0212036A (pt) 2004-08-17

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212036-4A BR0212036A (pt) 2001-08-21 2002-08-16 Composições farmacêuticas compreendendo conjugados de polissacarìdeos para a inibição da metástase ou prevenção da recorrência de tumor maligno

Country Status (18)

Country Link
EP (1) EP1418947A1 (zh)
KR (1) KR20040027972A (zh)
CN (1) CN100372570C (zh)
AR (1) AR035137A1 (zh)
AU (1) AU2002328093B2 (zh)
BR (1) BR0212036A (zh)
CA (1) CA2457056C (zh)
HU (1) HUP0401351A3 (zh)
IL (1) IL160148A0 (zh)
MX (1) MXPA04001599A (zh)
NO (1) NO20041194L (zh)
NZ (1) NZ530947A (zh)
PL (1) PL368319A1 (zh)
RU (1) RU2275913C2 (zh)
TW (1) TWI313609B (zh)
UA (1) UA75450C2 (zh)
WO (1) WO2003015826A1 (zh)
ZA (1) ZA200400917B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
EP2313487B1 (en) 2008-07-16 2018-04-04 Children's Medical Center Corporation Organ mimic device with microchannels and methods of use
WO2012166903A1 (en) * 2011-06-02 2012-12-06 President And Fellows Of Harvard College Methods and uses for ex vivo tissue culture systems
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
BR122021014396B1 (pt) * 2012-10-11 2022-07-05 Daiichi Sankyo Company, Limited Compostos intermediários ligantes de fármacos, e ligante
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
BR112016013482B1 (pt) 2014-01-31 2022-04-19 Daiichi Sankyo Company, Limited Conjugado de anticorpo anti-her2-fármaco, fármacos antitumor e/ou anticâncer e composição farmacêutica
JP6948951B2 (ja) 2015-05-04 2021-10-13 ファイザー・インク B群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
IL290959B2 (en) 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Preparations containing antibody-drug conjugates and methods for their production
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
CN112351999A (zh) 2018-05-18 2021-02-09 第一三共株式会社 抗-muc1抗体-药物缀合物
TWI822822B (zh) 2018-07-31 2023-11-21 日商第一三共股份有限公司 抗體-藥物結合物之用途
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195324T1 (de) * 1993-02-26 2000-08-15 Drug Delivery System Inst Ltd Polysaccharidderivat und wirkstoffträger
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
JP4420472B2 (ja) * 1996-04-15 2010-02-24 旭化成株式会社 薬物複合体
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (zh) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 低收缩性光固化涂层材料及其制法和用途
CA2333321A1 (en) * 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Drug complex

Also Published As

Publication number Publication date
RU2004108141A (ru) 2005-04-20
PL368319A1 (en) 2005-03-21
NZ530947A (en) 2006-04-28
HUP0401351A2 (hu) 2004-12-28
CA2457056A1 (en) 2003-02-27
NO20041194L (no) 2004-03-19
AU2002328093B2 (en) 2005-05-05
HUP0401351A3 (en) 2011-02-28
KR20040027972A (ko) 2004-04-01
UA75450C2 (en) 2006-04-17
CA2457056C (en) 2008-07-22
CN100372570C (zh) 2008-03-05
WO2003015826A1 (en) 2003-02-27
TWI313609B (en) 2009-08-21
CN1545423A (zh) 2004-11-10
EP1418947A1 (en) 2004-05-19
RU2275913C2 (ru) 2006-05-10
ZA200400917B (en) 2004-08-25
MXPA04001599A (es) 2004-07-08
AR035137A1 (es) 2004-04-14
IL160148A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
BR0212036A (pt) Composições farmacêuticas compreendendo conjugados de polissacarìdeos para a inibição da metástase ou prevenção da recorrência de tumor maligno
ATE532790T1 (de) Einschlussverbindung mit cucurbiturilderivaten als wirtsmolekül, und diese enthaltende pharmazeutische zusammensetzung
DE60037020D1 (en) Anilinochinazoline als protein-tyrosin-kinasehemmer
BR9807824A (pt) Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
TR199900049T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler.
TR200500745T2 (tr) Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
TR200200717T2 (tr) Terapötik kinazolin türevleri.
EE200400033A (et) Vähelahustuvaid ja/või happetundlikke ravimeid janeutraliseeritud happelisi polümeere sisaldavad farmatseutilised kompositsioonid
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
TR200201082T2 (tr) Glikopriranoziloksipirazol türevleri
BRPI0203172B8 (pt) composição farmacêutica para acondroplasia
BR0315580A (pt) Derivados de metileno uréia
BRPI0110024B8 (pt) derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
ATE422356T1 (de) Pharmazeutische zubereitungen
ATE249842T1 (de) Zielgerichte arzneimittel abgabe für zulphonamide-derivate
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
WO2001042243A3 (en) Protein kinase inhibitors
BRPI0413384A (pt) inibidores da proteìna farnesil transferase como agentes antitumores

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MITSUBISHI TANABE PHARMA CORPORATION (JP)

Free format text: ALTERADO DE: TANABE SEIYAKU CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/61 (2017.01), A61K 47/65 (2017.01), A61P 3